9 Results for "

CL2A

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "CL2A" in MCE Product Catalog:

11
11 Publications Verification
Cat. No.: HY-132254
CAS No.: 1491917-83-9
Purity:  99.13%
Synonyms: IMMU-132
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
11
11 Publications Verification
Cat. No.: HY-132254A
CAS No.: 1491917-83-9
Purity:  96.61%
Synonyms: IMMU-132 (solution)
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128946
CAS No.: 1279680-68-0
Purity:  99.07%
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .
loading...
    loading...
Cat. No.: HY-128945
CAS No.: 2616704-22-2
Purity:  99.49%
Target:  

ADC Linkers

Research Areas:  

Inflammation/Immunology Cancer

CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker .
loading...
    loading...
Cat. No.: HY-164668
Research Areas:  

Cancer

ADC Control Human IgG1-SN-38 is an isotype control of ADC Human IgG1-SN-38. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946).
loading...
    loading...
Cat. No.: HY-170868
CAS No.: 3025194-00-4
Research Areas:  

Cancer

CL2A-FL118 is a drug-linker for synthesis of ADC molecule Sac-CL2A-FL118 .
loading...
    loading...
Cat. No.: HY-160825
CAS No.: 1846605-04-6
Target:  

ADC Linkers

Research Areas:  

Cancer

CL2A acid is a ADC linker for synthesis of Antibody-drug conjugates (ADCs)
loading...
    loading...
Cat. No.: HY-128945A
Target:  

ADC Linkers

Research Areas:  

Inflammation/Immunology Cancer

CL2A TFA is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A TFA is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker .
loading...
    loading...
Cat. No.: HY-128947
CAS No.: 2270986-66-6
Target:  

ADC Linkers

Research Areas:  

Cancer

CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in agent substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1/2 ~20 hours) [2].
loading...
    loading...